Sugi Predict

Sugi Predict / Compounds / SCHEMBL2265102

SCHEMBL2265102

SCHEMBL2265102

FC(F)(Cl)c1nnc2ccc(Cl)nn12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 1.00
▸ SMN1; SMN2 Q16637 2/20 1.00
▸ ALDH1A1 P00352 4/20 0.77
▸ HTT P42858 2/20 0.52
▸ DYRK1A Q13627 2/20 0.44
▸ DYRK2 Q92630 2/20 0.44
▸ TDP1 Q9NUW8 1/20 0.42
▸ GAA P10253 1/20 0.41
▸ CYP1A2 P05177 2/20 0.40
▸ SCN5A Q14524 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ CCNA2 P20248 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ CDK5 Q00535 1/20 0.38
▸ CDK5R1 Q15078 1/20 0.38
▸ DYRK1B Q9Y463 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL750158 0.87 ALDH1A1 (1.00) KDM4ESMN1; SMN2ALDH1A1HTTDYRK1A
SCHEMBL2267586 0.84 ALDH1A1 (0.75) KDM4ESMN1; SMN2ALDH1A1HTTDYRK1A
SCHEMBL20203879 0.84 ALDH1A1 (0.75) KDM4ESMN1; SMN2ALDH1A1HTTDYRK1A
SCHEMBL22744857 0.84 ALDH1A1 (0.75) KDM4ESMN1; SMN2ALDH1A1HTTDYRK1A
SCHEMBL2268505 0.80 ALDH1A1 (0.69) KDM4ESMN1; SMN2ALDH1A1HTTDYRK1A
SCHEMBL24616729 0.80 ALDH1A1 (0.69) KDM4ESMN1; SMN2ALDH1A1HTTDYRK1A
SCHEMBL6631672 0.80 ALDH1A1 (0.69) KDM4ESMN1; SMN2ALDH1A1HTTDYRK1A
SCHEMBL7225078 0.73 ALDH1A1 (0.59) KDM4ESMN1; SMN2ALDH1A1HTTDYRK1A
SCHEMBL612506 0.72 KDM4E (1.00) KDM4ESMN1; SMN2ALDH1A1DYRK1ADYRK2
SCHEMBL20203863 0.72 ALDH1A1 (0.58) KDM4ESMN1; SMN2ALDH1A1DYRK1ADYRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376475-A1 ION CHANNEL MODULATORS PRAXIS PREC MEDICINES INC (US) 2025-12-11 — — US disclosed
US-12479844-B2 Ion channel modulators PRAXIS PRECISION MEDICINES, INC. (US) 2025-11-25 — — US disclosed
US-20250163068-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2025-05-22 — — US disclosed
CN-119371426-A Ion channel modulators 普拉克西斯精密药物股份有限公司 2025-01-28 — — CN disclosed
CN-119350320-A Ion channel modulators 普拉克西斯精密药物股份有限公司 2025-01-24 — — CN disclosed
EP-4487916-A2 ION CHANNEL MODULATORS Praxis Precision Medicines, Inc. (US) 2025-01-08 — — EP disclosed
EP-4397308-A2 COMPOUNDS AND THEIR METHODS OFUSE Praxis Precision Medicines, Inc. (US) 2024-07-10 — — EP disclosed
US-20240132501-A1 ION CHANNEL MODULATORS PRAXIS PRECISION MEDICINES, INC. (US) 2024-04-25 — — US disclosed
EP-3548033-B1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2024-04-10 — — EP disclosed
CN-117756800-A Ion channel modulators 普拉克西斯精密药物股份有限公司 2024-03-26 — — CN disclosed
EP-3801535-A1 ION CHANNEL MODULATORS Praxis Precision Medicines, Inc. (US) 2021-04-14 — — EP disclosed
US-20210087197-A1 ION CHANNEL MODULATORS PRAXIS PRECISION MEDICINES, INC. 2021-03-25 — — US disclosed
US-20210087197-A1 ION CHANNEL MODULATORS PRAXIS PRECISION MEDICINES, INC. 2021-03-25 — — US disclosed
EP-3548033-A1 COMPOUNDS AND THEIR METHODS OF USE Praxis Precision Medicines, Inc. (US) 2019-10-09 — — EP disclosed
WO-2018098499-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2018-05-31 — — WO disclosed
WO-2018098499-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2018-05-31 — — WO disclosed
US-8003649-B2 Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 ASTRAZENECA AB (SE) 2011-08-23 — — US disclosed
EP-2235010-A1 BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS AstraZeneca AB (SE) 2010-10-06 — — EP disclosed
US-20100016279-A1 BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 ASTRAZENECA AB (SE) 2010-01-21 — — US disclosed
WO-2009081197-A1 BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS ASTRAZENECA AB (SE) 2009-07-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132501-A1 ION CHANNEL MODULATORS SCN1A, SCN3A, SCN2A KDM4E 2324/4885SMN1; SMN2 185/4885ALDH1A1 1953/4885
US-20210087197-A1 ION CHANNEL MODULATORS SCN1A, SCN3A, SCN2A KDM4E 2324/4885SMN1; SMN2 185/4885ALDH1A1 1953/4885
US-20250163068-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B KDM4E 2066/4885SMN1; SMN2 334/4885ALDH1A1 916/4885
US-12479844-B2 Ion channel modulators SCN1A, SCN3A, SCN2A KDM4E 2324/4885SMN1; SMN2 185/4885ALDH1A1 1953/4885
US-20250376475-A1 ION CHANNEL MODULATORS SCN1A, SCN3A, SCN2A KDM4E 2324/4885SMN1; SMN2 185/4885ALDH1A1 1953/4885
US-20100016279-A1 BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 AR, NR5A1, CYP17A1 KDM4E 3067/4885SMN1; SMN2 3399/4885ALDH1A1 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.